Prasugrel – what is known in 2010? Review article
Article Sidebar
Published:
Jun 30, 2010
Keywords:
prasugrel, clopidogrel, acute coronary syndrome, TRITON TIMI 38 trial
Main Article Content
Abstract
Dual antiplatelet theraphy with an aspirin and a thienopyridine is a cornerstone of tratment to prevent thrombosis complications of acute coronary syndromes (ACS). Clopidogrel is accepted as a keycomponent of antiplatelet theraphy in patient with ACS. Prasugrel is a novel thienopyridine that reduces new or recurent myocardial infarctions compared with clopidogrel in patients with ACS undergoing percutaneous intervention. The efficacy of prasugrel was established through the TRITON TIMI 38 trial which was published in 2007. Till now, several subanalysis of TRITON were published. In article new data for prasugrel are presented.
Article Details
How to Cite
Janiszewski , M., & Chmielewski , M. (2010). Prasugrel – what is known in 2010?. Medycyna Faktow (J EBM), 3(2(7), 57-61. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2605
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wiviott S.D., Trenk D., Frelinger A.L. et al. (for the PRINCIPLE-TIMI 44 Investigators): Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007; 116: 2923-2932.
2. Wiviott S.D., Braunwald E., McCabe C.H. et al. (for the TRITON–TIMI 38 Investigators): Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2007; 357: 2001-15.
3. Wiviott S.D., Braunwald E., Angiolillo D.J. et al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008 Oct 14; 118(16): 1626-36.
4. Antman E.M., Wiviott S.D., Murphy A.S. et al.: Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention A TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis. J. Am. Coll. Cardiol. 2008; 51: 2028-2033.
5. Pride Y.B., Wiviott S.D., Buros J.L. et al.: Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am. Heart J. 2009 Sep; 158(3): e21-6.
6. Morrow D.A., Wiviott S.D., White H.D. et al.: Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009 Jun 2; 119(21): 2758-64.
7. Mahoney E.M., Wang K., Arnold S.V. et al.: Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010 Jan 5; 121(1): 71-9.
2. Wiviott S.D., Braunwald E., McCabe C.H. et al. (for the TRITON–TIMI 38 Investigators): Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2007; 357: 2001-15.
3. Wiviott S.D., Braunwald E., Angiolillo D.J. et al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008 Oct 14; 118(16): 1626-36.
4. Antman E.M., Wiviott S.D., Murphy A.S. et al.: Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention A TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis. J. Am. Coll. Cardiol. 2008; 51: 2028-2033.
5. Pride Y.B., Wiviott S.D., Buros J.L. et al.: Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am. Heart J. 2009 Sep; 158(3): e21-6.
6. Morrow D.A., Wiviott S.D., White H.D. et al.: Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009 Jun 2; 119(21): 2758-64.
7. Mahoney E.M., Wang K., Arnold S.V. et al.: Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010 Jan 5; 121(1): 71-9.